Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
NCT06701838 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15
Last updated 2024-12-03
Summary
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress. But too much cortisol can lead to problems like weight gain, high blood pressure, diabetes, and changes in appearance, such as a round face or a hump on the back. People with Cushing's disease often gain weight around their belly and may get stretch marks. They might also feel emotional changes, tiredness, or weakness. This disease is usually caused by a small, non-cancerous growth in the pituitary gland called a 'pituitary adenoma.' The pituitary gland is a small organ at the base of the brain and controls many important functions.
When someone is diagnosed with Cushing's disease, doctors typically use an MRI scan to look for the adenoma in the pituitary gland. If found, the adenoma can often be removed through surgery, which often cures the disease. This is the standard treatment for patients with Cushing's disease. However, MRIs only find the adenoma in about 60% of the time. If surgery isn't possible because the adenoma can't be located, doctors may use medication to lower cortisol levels.
In addition to the MRI, doctors might use a special PET/CT scan to find the adenoma. This PET/CT scan is not available everywhere, so the investigators refer our patients to Cambridge Hospital for this scan, which uses a special dye called 11C-methionine.
The investigators then review the scan with the teams from Imperial and Cambridge. If the PET/CT scan shows where the adenoma is, the patient will be offered surgery. However, finding the adenoma can be challenging because they are often small and hard to distinguish from normal tissue.
If the adenoma isn't visible, the investigators will use medical treatment to lower cortisol. After a period of medical treatment, another MRI scan and PET/CT scan will be done to see if the adenoma has become clearer. This second PET/CT scan would not normally be part of routine clinical care. The investigators will then compare the results of the two scans to see if the special dye is showing a stronger signal, which can help us find the adenoma more accurately and improve the chance of curing Cushing's disease with surgery.
Conditions
- Cushing's Disease
- Hypercortisolism
- Pituitary Adenoma
- Pituitary ACTH Secreting Adenoma
Interventions
- DIAGNOSTIC_TEST
-
11C-Methionine PET/CT
After a 3-month period of eucortisolaemia, patients will undergo a second MRI of the pituitary gland and 11C-methionine PET/CT scan with SUVmax ratio analysis of the presumed corticotroph pituitary adenoma.
Sponsors & Collaborators
- collaborator OTHER
-
Imperial College London
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-03
- Primary Completion
- 2026-07-05
- Completion
- 2026-07-05
More Related Trials
-
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
NCT03080181 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
NCT07104812 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
NCT02180217 ·Status: COMPLETED ·Phase: PHASE3
-
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake
NCT06556277 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02860923 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00936741 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Metyrapone in Patients With Hypercortisolism
NCT05255900 ·Status: COMPLETED
-
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
NCT01504555 ·Status: UNKNOWN
-
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
NCT00677313 ·Status: COMPLETED ·Phase: NA
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma
NCT01382420 ·Status: UNKNOWN ·Phase: NA
-
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
NCT04897802 ·Status: COMPLETED ·Phase: PHASE4
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
NCT04543253 ·Status: RECRUITING
-
Effects of Mindfulness Therapy in Patients With Acromegaly and Cushing
NCT04420000 ·Status: COMPLETED ·Phase: NA
-
Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine
NCT00617058 ·Status: TERMINATED ·Phase: PHASE2
-
Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers
NCT03844217 ·Status: COMPLETED ·Phase: NA
-
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846 ·Status: COMPLETED ·Phase: PHASE4
-
Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis
NCT01939093 ·Status: COMPLETED ·Phase: PHASE4
-
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
NCT02889224 ·Status: COMPLETED ·Phase: NA
-
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
NCT00426608 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolic Effects of Antipsychotics in Children
NCT00205699 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
NCT06754163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Metabolic Side-effects for Second-generation Antipsychotics
NCT01280396 ·Status: COMPLETED
-
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
NCT07045935 ·Status: RECRUITING ·Phase: PHASE4
-
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
NCT07138274 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2